Universität zu Köln

Rottlaender, D., Reda, S., Motloch, L. J. and Hoppe, U. C. (2011). New tyrosine kinase and EGFR inhibitors in cancer therapy. Internist, 52 (10). S. 1245 - 1254. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Full text not available from this repository.

Abstract

Cardiotoxicity is a serious side effect of targeted molecular therapies in cancer treatment. Monoclonal antibodies and tyrosine kinase inhibitors are known to be potent therapies in various neoplastic diseases due to inhibition of specific signal transduction pathways. Although targeted therapies are considered to be less toxic and better tolerated than common chemotherapies certain cardiac side effects have been observed. Cardiac toxicity may range from asymptomatic reduction of left ventricular function to life-threatening events like heart failure and acute coronary syndrome. Further side effects are arterial hypertension, thrombosis and arrhythmias. Cardiovascular side effects are common for anti-HER2 therapy in combination with anthracyclines and for inhibitors of angiogenesis. In these patients careful cardiac monitoring is warranted. Because of missing randomized long-term follow-ups, information about cardiac side effects is limited in newly developed targeted molecular therapies. In case of cardiac side effects or preexisting cardiac disease before therapy initiation, assessments by a cardiologist throughout the course of treatment are important. For patients with severe cardiac side effects, discontinuation of treatment is warranted; in case of asymptomatic cardiac side effects symptom-specific therapy should be performed.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Rottlaender, D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Reda, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Motloch, L. J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoppe, U. C. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-488124
DOI:	10.1007/s00108-011-2895-3
Journal or Publication Title:	Internist
Volume:	52
Number:	10
Page Range:	S. 1245 - 1254
Date:	2011
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-1289
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language IMATINIB RESISTANCE; CARDIOTOXICITY; PLUS; TRASTUZUMAB; SUNITINIB; HERCEPTIN; FAILURE; HEART Multiple languages Medicine, General & Internal Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/48812